



## Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

April 1, 2025

MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

- A fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 9, 2025. A live webcast will be available using this weblink: <https://wsw.com/webcast/stifel99/celc/2065375>; and
- A fireside chat at the 24<sup>th</sup> Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025. A live webcast will be available using this weblink: <https://wsw.com/webcast/needham146/celc/2212811>.

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at <https://ir.celcuity.com/events-presentations/> with a replay available shortly after the live events.

### About Celcuity

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR ("PAM") pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K $\alpha$ , AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at [ClinicalTrials.gov](https://clinicaltrials.gov). A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at [www.celcuity.com](http://www.celcuity.com). Follow us on [LinkedIn](#) and [Twitter](#).

[View source version of release on GlobeNewswire.com](#)

### Contacts:

Celcuity Inc.

Brian Sullivan, [bsullivan@celcuity.com](mailto:bsullivan@celcuity.com)

Vicky Hahne, [vhahne@celcuity.com](mailto:vhahne@celcuity.com)

(763) 392-0123

ICR Healthcare

Patti Bank, [patti.bank@icrhealthcare.com](mailto:patti.bank@icrhealthcare.com)

(415) 513-1284



News Provided by GlobeNewswire via QuoteMedia